R&D Tax Credit Gap and Capital Investment Misallocation
Problem
The U.S. R&D tax credit was eliminated from 2022-2025, weakening corporate R&D investment. Housing investment is crowding out capital for productive output. Federal research funding lacks equity strings, resulting in unclear ownership and underutilized outcomes in pharmaceuticals.
Pain points
- R&D tax credit eliminated from 2022-2025
- Housing investment crowds out productive capital
- Federal research funding lacks equity strings, causing ambiguous ownership
Questions to verify
- Have you been directly affected by the R&D tax credit cancellation in your R&D budget?
- Do you believe housing investment is crowding out capital allocation for technology R&D?
- Do you agree that federal research funding should come with equity strings to ensure public benefit?
Evidence
quote · @匿名
the R&D tax credit was gone from 2022 - 2025 thanks to the Tax Cuts and Jobs Act signed in 2017.
quote · @匿名
the big problem is housing. When housing becomes the best investment, it cannibalizes capital investment into productive output.
quote · @匿名
federal research dollars should come with equity strings attached in the results.
Disclaimer: this card is distilled by AI from community discussions as “pain point evidence”. It is a starting point for need analysis and validation, not a “validated market need”. AI has analytical limits; please open the original discussion above to manually verify before key decisions.